Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Pharmaceuticals Ltd.

www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Ltd.

Glenmark’s Lonhala Version Hits ‘Intriguing’ Indian Nebulizer Market

Glenmark’s nebulized, long-acting muscarinic antagonist for COPD has hit the Indian market. Delivered via a novel mesh nebulizer, it is seen as likely catering to a relatively small patient group.
Commercial Strategy

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Biosimilars Market Access
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register